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Abstract
Drug targeting is a process by which the distribution of drug in an organism is deployed
in such a manner that its major fraction interacts exclusively with the target tissue at the
cellular or subcellular level. Magnetic drug targeting is one of the major drug delivery
methods due to its noninvasiveness, high targeting efficiency, and minimized toxic side
effects on healthy cells and tissues. There are several experimental works on the magnetic
drug targeting through microvessel, but very few works are carried out on the mathemat-
ical models on magnetic drug delivery. The aim of the present chapter is to discuss all
major and minor factors, such as fluidic force, magnetic force, particle-particle interaction,
inertia force, Saffman lift force, permeability of the microvessel and carrier particle, and so
on, which influenced the drug targeting through microvessel by considering the nature of
blood flow as Newtonian, non-Newtonian, single phase, and two phase model. A brief
details of fluidic force, magnetic force, particle-particle interaction, Saffman force, buoy-
ancy force, etc. Mathematical models on the fluidic force are discussed for Newtonian,
non-Newtonian fluid, single phase, and two-phase fluid model including other forces that
influence the magnetic drug targeting in microvessel.
Keywords: magnetic drug targeting, mathematical model, non-Newtonian fluid,
single phase, two-phase flow
1. Introduction
Magnetic micro- and nanoparticles are finding increasing use in different fields of microbiol-
ogy, biomedicine, and biotechnology where they are used to transport and separate materials,
label, and to deliver therapeutic drugs to a target tissue. The use of the magnetic particles as
transport agents in different bio-applications has been discussed by Furlani [1]. They have
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discussed the advantages of using magnetic nanoparticles which are well suited for the differ-
ent bio-applications due to the following reasons: (1) they are nontoxic and well tolerated by
living organisms after being well synthesized and functionalized; (2) they can be synthesized in
sizes that range from a few nanometers to higher ranges with a very narrow interval. This nature
makes them ideal for probing and manipulating bioparticles and biosystems of different ranges
such as protein (5–50 nm), viruses (20–50 nm), genes (2 nmwide and 10–100 nm long), or whole
cells (10–100 μm). It is also noted that sub-micron and micron-sized magnetic nanoparticles are
used in different bio-applications; (3) magnetic nanoparticles are very familiar with custom-
tailored surface treatment to enhance biocompatibility and enable coating with affinity bio-
molecules for highly specific binding with a target biomaterial; (4) magnetic nanoparticles can
easily be magnetized by an applied magnetic field, but once field is removed, it reverts back to
an unmagnetized state. This behavior can easily be used to separate or immobilize magneti-
cally labeled biomaterials from a carrier fluid using an external magnetic field. Significantly,
the relatively low permeability of an aqueous carrier fluid enables efficient magnet coupling to
an immersed magnetically labeled biomaterial. Moreover, the low intrinsic magnetic suscepti-
bility of most biomaterials provides substantial contrast between labeled and unlabeled
material, which enables a high degree of selectivity and detection. Magnetic labeling has
advantages over conventional fluorescence and chemiluminescence-based biolabels. Notably,
small samples of magnetically labeled material can be detected using ultra-sensitive ferromag-
netic “spin valve” sensors, which can be integrated into microfluidic-based diagnostic systems.
Magnetic particles have an additional advantage, mainly designed to absorb energy at a reso-
nant frequency from a time-varying magnetic field, which enables their use for therapeutic
hyperthermia of tumors. During radio frequency (RF) hyperthermia, magnetic nanoparticles are
directed to malignant tissue and then irradiated with an AC magnetic field of sufficient magni-
tude and duration to heat the tissue to 42C for 30 min or more, which is sufficient to destroy the
tissue (Moroz et al., [2]). In the samemanner, it will be used for other cancer therapies (Hergt and
Duzt [3]; Gupta and Gupta [4]; Shaw and Murthy [5–7]). Magnetic nanoparticles are also used
for bioimaging, both optically, using surface-bound fluorophores for biophotonic applications
(Kircher et al. [8]; Sahoo et al. [9]; Sosnovik et al. [10]; Prasad [11]; Levy et al. [12]; Medarova et al.
[13]) and magnetically where they serve as contrast agents for enhanced MRI.
Drug targeting is a process by which the distribution of drug in an organism is deployed in
such a manner that its major fraction interacts exclusively with the target tissue at the cellular
or subcellular level. Magnetic drug targeting is one of the major drug delivery methods due to
its noninvasiveness, high targeting efficiency, and minimized toxic side effects on healthy cells
and tissues (Lübbe et al. [14]; Alexiou et al. [15]). This drug targeting is mainly used for the
medical treatment of various diseases, especially cancer, and cardiovascular and endovascular
diseases, such as stenosis, thrombosis, aneurysm, atherosclerosis (Jurgons et al. [16]), trancheo-
bronchial airways (Pourmehran et al. [17]), and so on. Magnetic drug targeting is a growing
interest with recent progress in the development of carrier particles that are designed to target
a specific tissue and effect local chemo-, radio- and gene therapy at the tumor site (Figure 1)
(Fabrizio and Francois [18]; Berryl and Curtis [19]).
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Magnetic drug targeting is one of the growing interests with recent progress in the develop-
ment of carrier particles that are designed to target a specific tissue to cure the tumor. In
magnetic drug targeting, the therapeutic agent can be either encapsulated into a magnetic
micro- or nanosphere or conjugated on its surface. Magnetic particles with bound drug mole-
cules are injected into the vascular system upstream from the malignant tissue (Figure 2). They
can be immobilized at the tumor site using a local magnetic field gradient produced by an
external field source. Particle accumulation at the tumor is often augmented by magnetic
agglomeration, and the efficiency of the accumulation depends on various physiological
parameters including particle size, surface characteristics, field strength, blood flow rate, and
so on (Figure 3).
Upon achieving a sufficient particle concentration at a tumor, drug molecules can be released
from their carrier particles by changing physiological conditions such as pH, osmolality, or
temperature, or by enzymatic activity (Berry and Curtis [19]; Arrueboa et al. [21]). Since the
therapeutic agents are localized to regions of diseased tissue, higher dosages can be applied,
which enables more effective treatment. This is in contrast to less selective conventional
chemotherapy wherein a toxic drug is distributed systemically throughout the body, poten-
tially harming healthy tissue.
Figure 1. Schematic illustration of multifunctional and stimuli-responsive porous carrier particle, which is modified with
specific antibodies, ligands targeting the cell surface, and anti-adhesive molecules (shown in the red area), and loaded
with magnetic particles, fluorescent agents, and drugs for imaging, detection, and therapy (shown in the blue area). It is
synthesized from stimuli-responsive polymers or modified with responsive molecules, which can respond to the change
of environmental stimuli like pH, light, heat, oxides, and so on. (shown in the yellow area) (Fan et al. [20]).
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During magnetic drug targeting, beyond fluidic force and magnetic force, there are several
factors that play a different role in the phenomena. They are related to blood flow such as
particle-particle interaction (mainly for the vessel with small radius), Saffman lift force, and so
on. Some of them related to the drug particles e.g., drag force, interparticle effects such as
Figure 2. Noninvasive magnetic drug targeting in a microvessel (Furlani [1]).
Figure 3. Drug-loaded carrier is typically composed of a magnetic core and a biocompatible coating material. The
magnetic core was made from different materials such as Fe3O4, Fe2O3, or Fe. The coating materials are Au, PEG, or
SiO2. Based on the biokinetics of particles, a drug carrier ranging from 10 to 200 nm in diameter is optimal for in vivo
delivery, as the small particles (D < 10 nm) escape by renal clearance and the large ones (D > 200 nm) are sequestered by
the reticuloendothelial system of the spleen and liver (Lunnoo and Puangmali [22]).
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magnetic dipole interactions, particle-blood cell interaction, etc. Here, one by one, we discuss
different forces that directly influence the trajectories of the carrier particle and on magnetic
drug targeting.
2. Magnetic force on the particle
Magnetic force on the particle that flows with the fluid is well described by Furlani and Furlani
[23]. By linear magnetization model, relation of magnetization and intensity of the magnetic
field in the saturation can be written as
Msp ¼ χpHin, sat, (1)
where χp ¼ μp=μ0  1 is the susceptibility of the particle, μp is the permeability of the particle,
and μ0 is the permeability of air. The magnetic force is determined by “effective” dipole
moment method as described by Jones [24] and Furlani [25]. In this method, the magnetized
particle will be replaced by an “equivalent” point dipole with a moment mp, eff , and the force
on the dipole (and hence on the particle) is given by
Fm ¼ μf meff :∇
 
Ha, (2)
where μf is the permeability of the transport fluid, meff is the effective dipole moment of the
particle, and Ha is the externally applied magnetic field intensity at the center of the particle,
where the equivalent dipole is located. Firstly, we solve the magneto-static boundary value
problem for the particle (here the considered shape of the particle is spherical, and it may change
according to the shape) immersed in a fluidwhere themagnetizationMp is parallel to the applied
field and then determine the equivalent point dipole moment mp, eff . Spherical coordinate system
(r:θ, ϕÞ is considered for the spherical particle with origin as the center of the spherical particle.
Cartesian coordinates (x, y, z) are considered for the microvessel and magnet (see Figure 4).
The potential field inside and outside of the particle can be written as
Φin r;θð Þ ¼ ∇Hin ¼ Cinrcos θð Þ r < Rp
 
: (3)
Φout r;θð Þ ¼ ∇Hout ¼ Ha rcos θð Þ þ Cout
cos θð Þ
r2
r ≥Rp
 
: (4)
where Rp is the radius of the spherical particle. Moreover, we considered z axis in the direction
of applied magnetic field. The magnitude of the field intensity inside the particle in the z axis is
Hin,z ¼ 
∂
∂r
Φin r;θð Þ
 
cos θð Þ þ
1
r
∂
∂r
Φin r;θð Þ
 
sin θð Þ: (5)
The corresponding boundary condition with respect to the potential inside and outside the
particle surface and normal component of resultant of the magnetic force are written as:
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Φin r;θð Þ ¼ Φout r;θð Þ,
μ0
∂
∂r
Φin þMp
 
¼ μf
∂
∂r
Φout:
(6)
Solving Eqs. (3) and (4) with boundary condition (6), we get
Cin ¼
3μf
μ0 þ 2μf
Ha 
μ0
μ0 þ 2μf
Ma, (7)
and
Cout ¼ R
3
p
μ0  μf
μ0 þ 2μf
Ha þ
μ0
μ0 þ 2μf
Ma
 !
: (8)
From the definition (see Eq. (3)), it is clear that Hin ¼ Cin and if the particle is below the
saturation, then Mp ¼ χpHin. By substituting these two relations in Eq. (7), we get:
Figure 4. Geometry and reference frame for analysis: (a) coordinate systems and reference frames, (b) magnetic flux lines
for a cylinder magnet, cross-section of microvessel with reference frame (Furlani [23]).
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Hin ¼
3 χf þ 1
 	
χp  χf
 	
þ 3 χf þ 1
 	Ha, (9)
and
Mp ¼ χpHin ¼
3χp χf þ 1
 	
χp  χf
 	
þ 3 χf þ 1
 	Ha: (10)
The magnitude of the “equivalent” dipole for the particle is related to Cout, and it can be
written as
mp, eff ¼ 4πCout ¼ Vp
3 χp  χf
 	
χp  χf
 	
þ 3 χf þ 1
 	Ha, (11)
where Vp ¼ 4=3ð ÞπR
3
p which is the volume of the spherical particle.
Substituting Eq. (11) into Eq. (2), we can define the magnetic force in the form of
Fm ¼ μfVp
3 χp  χf
 	
χp  χf
 	
þ 3 χf þ 1
 	 Ha:∇ð ÞHa: (12)
Now when the susceptibility of the fluid is very small (i.e., χf







≪ 1), then μf ≈μ0 and hence
Eq. (12) can be written as
Fm ¼ μ0Vp
3 χp  χf
 	
χp  χf
 	
þ 3 χf þ 1
 	 Ha:∇ð ÞHa: (13)
In similar fashion,
Hin ¼
3
χp  χf
 	
þ 3
Ha, (14)
and
mp, eff ¼ Vp
3 χp  χf
 	
χp  χf
 	
þ 3
Ha: (15)
In general, the effective dipole moment can be written as
mp, eff ¼ Vpf Hað ÞHa, (16)
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where
f Hað Þ ¼
3 χp  χf
 	
χp  χf
 	
þ 3
, Ha <
χp  χf
 	
þ 3
3χp
0
@
1
AMsp
Msp=Ha, Ha <
χp  χf
 	
þ 3
3χp
0
@
1
AMsp
jχf j << 1
 	
;
8>>>><
>>>>:
(17)
and Ha ¼ ∣Ha∣.
In this analysis, we assume that the magnet is infinitely extended in the y-direction, and
therefore the y component of the magnetic field and force is considered as zero.
So, the intensity of the magnetic field and magnetic force has two components along x axis
and z axis. The resultant of the intensity of the magnetic field is written as
Ηa ¼ Hax x; zð Þbx þHaz x; zð Þbz (18)
and similarly, the resultant of the magnetic force is written as
Fm ¼ Fmx x; zð Þbx þ Fmz x; zð Þbz, (19)
where
Fmx x; zð Þ ¼ μ0Vp f Hað Þ Hax x; zð Þ
∂Hax x; zð Þ
∂x
þHaz x; zð Þ
∂Hax x; zð Þ
∂z
 
, (20)
and
Fmx x; zð Þ ¼ μ0Vp f Hað Þ Hax x; zð Þ
∂Haz x; zð Þ
∂x
þHaz x; zð Þ
∂Haz x; zð Þ
∂z
 
: (21)
2.1. Magnetic field and force of a cylindrical magnet
Equations (20) and (21) represent the magnetic force for a rectangular cylinder whose y-axis
extends infinitely and components of the magnetic force act along x and z axis. The
calculation will be different for the case of cylindrical magnet. The cylindrical coordinate
system (r0,ϕ0) with origin as the center of the magnet is shown in Figure 4.
Components of the intensity of the magnetic field in cylindrical coordinates are written as
Hr0 r
0
;ϕ0
 	
¼
MsR
2
mag
2r02
cos ϕ0
 
, (22)
and
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Hϕ0 r
0
;ϕ0
 	
¼
MsR
2
mag
2r02
sin ϕ0
 
: (23)
Again, the geometry of the microvessel and flow nature is considered as the Cartesian coordi-
nate system, and so it is necessary to convert the cylindrical coordinate system into the general
Cartesian coordinate systems, say (x0, z0); then, the intensity of the magnetic field in the Carte-
sian coordinate system is written as:
Hx0 x
0
; z
0
 	
¼
MsR
2
mag
2
x02  z02
 	
x02 þ z02
 2 , (24)
Hz0 x
0
; z
0
 	
¼
MsR
2
mag
2
2x
0
z
0
x02 þ z02
 2 , (25)
and the corresponding field gradients is written as:
∂
∂x0
Hx0 x
0
; z
0
 	 	
¼
MsR
2
mag
2
x
0
3z02  x02
 
x02 þ z02
 3 , (26)
∂
∂z0
Hz0 x
0
; z
0
 	 	
¼
MsR
2
mag
2
z
0
z02  3x02
 
x02 þ z02
 3 , (27)
∂
∂z0
Hx0 x
0
; z
0
 	 	
¼
MsR
2
mag
2
z
0
z02  3x02
 
x02 þ z02
 3 , (28)
∂
∂z0
Hz0 x
0
; z
0
 	 	
¼ MsR
2
mag
x
0
x02  3z02
 
x02 þ z02
 3 : (29)
Finally, components of the magnetic field from Eqs. (20) and (21) with the help of expression
for intensity of the magnetic fields (Eqs. (26)–(29)) in a fixed Cartesian coordinate system (x, z)
with respect to the microvessel are written as:
Fmx x; zð Þ ¼ μ0Vp f Hað ÞM
2
sR
4
mag
xþ dð Þ
2 xþ dð Þ2 þ z2
h i3 , (30)
and
Fmx x; zð Þ ¼ μ0Vp f Hað ÞM
2
sR
4
mag
z
2 xþ dð Þ2 þ z2
h i3 , (31)
where d represents the distance between the axis of magnet and the carrier particle.
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This magnetic force is further simplified for noninvasive magnetic drug targeting. In this
procedure, the treatment takes place in such a way that there are no breaks in the skin, and
there are no contacts with skin break or mucosa, or internal body cavity beyond a natural or
artificial body orifice. In this case, the magnet is placed outside the body, and the distance from
the magnet to blood vessel is much larger than the diameter of the blood vessel, that is, d≫ x.
Furthermore, we used magnetite (Fe3O4) as a magnetic nanoparticle, which is highly biocom-
patible and for that the susceptibility of the magnetic particle is much larger, that is, χmp≫ 1.
Based on above two assumptions, the magnetic force components are simplified to:
Fmx x; zð Þ ¼ 
3μ0VpM
2
sR
4
mag
2 d2 þ z2
 3 , (32)
and
Fmx x; zð Þ ¼ 3μ0VpM
2
sR
4
mag
z
2 d2 þ z2
 3 , (33)
3. Fluidic force on the particle
Fluidic force mainly represents the drug force acts on the particle and it depends on the
velocity of the fluid. There are several phenomena, and studies have been carried out to
understand the blood flow though artery. Blood is a marvelous fluid. Blood consists of a
suspension of red blood cells (erythrocytes), white blood cells (leukocytes), and platelets in an
aqueous solution (plasma). All contain different density. The plasma is a transparent, slightly
yellowish fluid, and its density is about 1.035 gm/ml which can modeled as a Newtonian fluid.
The red blood cells are dominant particulate matter in blood with about 40–45% by volume of
the whole blood, and it plays a vital role in changing the viscosity of the blood. In general, we
use the term “hematocrit” to specify the volume percentage of red cells and entrained plasma.
Platelets are much smaller than red or white cells, and so it is not so significant for the nature of
blood while it plays a vital role in the formation of blood clots which may severely interfere
with the flow.
3.1. Fluidic force for single-phase flow (Newtonian fluid)
We start with a simple mathematical model for drag force. Here we considered blood as a
Newtonian fluid. This nature of the blood flow appears mainly for vessel of radius more than
1500 μm. The flow nature is well discussed by Furlani and Furlani [23]. Using Stokes’ approx-
imation, the fluidic force for the Newtonian fluid is written as:
Ff ¼ 6πηRcp vcp  vf
 
, (34)
where vcp is the velocity of the carrier particle, vf is the velocity of the fluid, and η is the
viscosity of the fluid. First, we are interested to find the drag force for Newtonian fluid.
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Assume that the blood vessel is cylindrical and the flow is laminar, fully developed, and
symmetric about the axis. So, the velocity profile is function of r (along the axis), and it is
written as
vf rð Þ ¼ 2vf 1
r
Rv
 2 !
, (35)
where vf is the average velocity of blood flow and Rv is the radius of the blood vessel.
With the help of Eq. (34), fluidic forces along the radial and axial radial direction are written as
Ffr ¼ 6piηRcpvp,x, (36)
and
Ffz ¼ 6piηRcp vcp,z  2vf 1
r
Rv
 2 !" #
: (37)
3.2. Fluidic force for single-phase flow (non-Newtonian fluid model)
The radius of the microvessel plays a vital role on the nature of the blood flow. It is observed
that the blood behaves as a non-Newtonian fluid due to low shear stress mainly when the
diameter of the vessel is less than 1300 μm. The blood in microvessel is more complex due to
the irregular geometry, mechanical behavior of blood, and its cellular constituents (mainly red
blood cells). It is well established that the Casson models hold satisfactory for the blood flow
through microvessel of diameter 130–1300 μm, while the Herschel-Bulkley model is more
suitable for the microvessel of radius 20–100 μm (Mishra et al. [26]; Prier et al. [27]; Bugliarello
and Sevilla [28]; Cokelet [29]; Merrill et al. [30]).
The drag force for the Newtonian fluid is different than the non-Newtonian fluid. The drag
force for the spherical particle is written as
CD ¼ CD Q
∗ð Þ ¼ 24X nð Þ=Q∗, (38)
where dynamic parameter Q∗ ¼ Re= 1þ Bið Þ2 with Reynolds number Re and Bingham number
Bi and X nð Þ is the rheological parameter.
For Casson fluid X nð Þ ¼ 1, while Reynolds and Bringham number is written as (Shaw et al.
[31])
ReCasson ¼
vcpdcpρ
ν
,BiCasson ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ρτy=ν
vcp=dcp
s
, (39)
where vcp and dcp are the reference velocity and diameter of the carrier particle ρ and ν are the
density and kinematic viscosity of the fluid.
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For Herschel-Bulkley fluid, the rheological parameter X nð Þ is defined in Table 1, and it is well
correlated by the following analytical expression (Renaud et al. [32])
X nð Þ ¼ 6 n1ð Þ=2
3
n2 þ nþ 1
 nþ1
: (40)
The Reynolds number and Birmingham number are written as
ReHB ¼
v2ncp d
n
cpρ
m
,BiHB ¼
τy
m vcp=dcp
 n , (41)
where m is the Herschel-Bulkley model parameter.
3.3. Shape of the carrier particle
The shape of the carrier particles plays a significant role in magnetic drug targeting. A
variety of nonspherical shapes including ellipsoids, discs, cylinders, hemispheres, cones,
and red blood cell-like bioconcave discoids have been shown to have an impact on biological
processes associated with the delivery of drugs (Geng et al. [33]; Canelas et al. [34]; Doshi
and Mitragotri [35]; Enayati et al. [36]). Several experimental and laboratorial scientists have
worked on the shape factor of particles in transport through the phagocytosis (Champion
and Mitragotri [37]), circulation half-life (Geng et al. [33]), endocytosis (Gratton et al. [38]),
targeting efficiency (Sutradhar et al. [39]), subsequent intracellular transport (Yoo et al. [40]),
and vasculature (Decuzzi et al. [41]). Spherical and non-spherical carrier particles plays an
imperative role on the passive drug targeting and bio-distribution of particles at the vascular
level (Champion et al. [37]; Decuzzi et al. [42]; Mitragotri [43]; Fox et al. [44]). An excellent
review of different shapes of carrier particles in drug delivery is given by Venkataraman
et al. [45] where they discuss different experimental observations in this field and point out
that understanding the implications of particle shapes would accelerate the development of
n X nð Þ
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.2
1.4
1.6
1.8
1.354
1.413
1.458
1.442
1.420
1.382
1.320
1.240
1.140
1.002
0.827
0.569
0.390
0.261
Table 1. Value of rheological parameter X(n) for different values of n.
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next-generation drug delivery vehicles. It is noted that the shape of the magnetic nanoparti-
cle does not change, and it is spherical in shape.
Due to the different shapes, the drag force on the carrier particle is modified as
CD ¼ CD Q
∗ð Þ ¼ 24k
0
X nð Þ=Q∗, (42)
where k0 is the shape constant which is defined as
k
0
¼
1, Sphere,ffiffiffiffiffiffiffiffiffiffiffiffiffi
β2  1
q
β1=3 ln βþ
ffiffiffiffiffiffiffiffiffiffiffiffiffi
β2  1
q  , Prolate ellipsoid,
2γ
3
1
lnγþ 0:193
, Cylinder,
8pi
3
, Circular disk:
8>>>>>>><
>>>>>>>>:
(43)
The fluidic force on the carrier particle in a laminar flow is written as
Ff ¼ 
1
2
ρAcpv
2
cpCD, (44)
where Acp is a reference cross-sectional area of the carrier particle.
With the help of Eq. (34), fluidic forces for the Casson fluid along the radial and axial radial
direction are written as
Ffr ¼ 12Acpηk
0 τy
η
 1=2
þ
vcp,x
dcp
 1=2" #2
, (45)
and
Ffz ¼ 12Acpηk
0 τy
η
 1=2
þ
vcp,z  vf
dcp
 1=2" #2
: (46)
However, fluidic forces for the Herschel-Bulkley fluid along the radial and axial radial direc-
tion are written as
Ffr ¼ 12AcpX nð Þk
0
τy þ η
vcp,x
dcp
 n 
, (47)
and
Ffz ¼ 12AcpX nð Þk
0
τy þ η
vcp,z  vf
dcp
 n 
: (48)
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3.4. Fluidic force for two-phase flow
Due to the microscopic properties of the blood and interaction among its different particles
(Blood cells, platelets) in plasma, the nature of blood flow leads a two-phase flow model with a
core of rouleaux surrounded by a cell-depicted peripheral layer. Due to the translation, deforma-
tion, and rotation, RBCs accumulated near the axis of the vessel and followed a constant velocity
while the plasma layer appears near the vessel wall and velocity profile follows a parabolic
profile. A mathematical model for a two-phase fluid model has been discussed by Seshadri and
Jaffrin [46] in which they have considered the outer layer as cell depleted, having a lower
hematocrit than the core region. Later, several researchers are worked on this direction (Gupta
et al. [47]; Srivastava [48]; Sankar and Lee [49]).
3.5. Glycocalyx layer and permeability of the microvessel
Permeability of the vessel is another important characteristic, which mainly influences the flow
nature of the blood. Due to the wall permeability, the fluid flows laterally and across the vessel
fenestrations/pores. Fluid flow through the porous medium is defined by the Darcy law and
extended Darcy law or Brinkman Law. Microvessel walls consist mainly of endothelial cell.
The vascular endothelium layer helps to regulate the material exchange between circulating
blood and the body tissues. The mechanism of the endothelium cells modulates microvessel
permeability. It is well known that the luminal surface of the vascular endothelium is lined
with a glycocalyx, a layer of membrane-bound macromolecules and adsorbed plasma pro-
teins. This glycocalyx layer is capable of reducing or restricting the plasma flow at the periph-
eral layer, near to the vessel wall. Moreover, the presence of the glycocalyx layer decreases the
effective cross-sectional area of the vessel available for plasma and red cell motion, so that it
would possibly cause an increase in flow resistance. The flow resistance highly depends on the
thickness of the glycocalyx layer. The flow resistance of the glycocalyx layer is more higher for
the thick layer with respect to the thin layer (Pries et al. [27]; Weinbaum et al. [50]; Sugihara-
Seki and Fu [51]). It is observed that the permeability of the microvessel significantly changes
from organ to organ with the location of the microvessel and is written in ascending order as
brain < skin < skeletal muscle < lung < heart <gastrointestinal tract< glomerulus of kidney.
3.6. Porosity of the carrier particle
In recent years, researchers are focused on the development of porous materials as controlled
drug delivery matrices due to its unique features such as stable uniform porous structure, high
surface area, tunable pore sizes with narrow distribution, and well-defined surface properties
(Sher et al. [52]; Shivanand and Sprockel [53]; Ahuja and Pathak [54]) (Figure 5). Due to these
wide physical flexibilities, porous carriers have been used in pharmaceuticals for many purposes
including development of novel drug delivery systems such as floating drug delivery system,
sustained drug delivery system, and improvement of solubility of poorly soluble drugs (Sharma
et al. [55]; Streubel et al. [56]). These materials possess larger amounts of nanopores that allow
the inclusion of drugs (Wang et al. [57]). Also, these features allow them to adsorb drugs and
release them in a more reproducible and predictable manner. The use of mesoporous,
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microporous, and nanoporous carriers for drug delivery is a part of growing research (Song et al.
[58]; Andersson [59]).
4. Particle-particle interaction
In a small vessel where diameter of the vessel is less than 500 μm, it is observed that the
apparent viscosity of blood is significantly decreased. This reduction of the apparent blood
viscosity with decreasing diameter is continued down to the diameter of approximately
10 μm. This phenomenon was first observed by Martini et al. [61] and at the same time by
Fahraeus and Lindqvist [62] during their vitro experiment to measure apparent viscosity of
blood in a small narrow glass tube. This phenomenon is called as the Fahraeus-Lindqvist effect
after their name. The reduction of the apparent viscosity of blood mainly appeared due to the
rotation and displacement of the deformable cells (mainly red blood cells) toward the tube axis
so that a cell-depleted region (mainly plasma) is formed near the wall. The effect of the cell-
depleted region does not significantly influence the apparent viscosity of blood for large
vessels (d > 500 μm) as the width of the cell-depleted layer is much smaller than the diameter
of the vessel. Pries et al. [63] compiled literature data on relative blood viscosity in tube flow
in vitro and obtained the empirical relationship between the relative apparent viscosity and
tube diameter for red cell suspensions with a hematocrit of 45% in glass tubes.
Figure 5. Electron microscopy images of porous Cu2O nanospheres (Zhu [60]).
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μapp
μ
 
0:45
¼ 220e1:3d þ 3:2 2:44e0:06d
0:645
, (49)
where μapp is the apparent viscosity, μ is the viscosity of the plasma, and d (in μm) is the
diameter of the tube. The apparent viscosity of blood for the medium-to-high flow velocities
(above 50 tube diameters/s) is written as
μapp
μ
¼ 1þ
μapp
μ
 
0:45
 1
 
1Hdð Þ
C  1
1 0:45ð ÞC  1
, (50)
where
C ¼ 0:8þ e0:075d
 
1þ
1
1þ 10 d=10ð Þ12
 !
þ
1
1þ 10 d=10ð Þ12
: (51)
Typical flow patterns of red blood cells in narrow tubes with different diameters are shown in
Figure 6. In all cases, at the wall where the highest shear stress occurs (wall shear stress), the
local viscosity of blood is the same as the viscosity of plasma ( 1:2 cP), which reduces the wall
shear stress and flow resistance.
Red blood cells are gathered near the axis of the vessel and so a cell-free region or low
hematocrit region appears near the wall of the vessel. Red blood cells flow faster than the cell-
depleted wall layer which mainly contains plasma and due to that the average velocity at the
core region (RBCs’ region) is much higher than the outer region (plasma region). This phe-
nomenon leads to a reduction of the tube hematocrit as compared to the discharged hemato-
crit. A simple schematic diagram of this model is given in Figure 6 where a steady laminar
flow of suspension of cells through a tube to or from a reservoir is considered. The problem
leads to conservation of mass, which is written as
HT=Hd ¼ US=UC, (52)
where HT and Hd represent the volume concentration of cells in the tube and in reservoir,
respectively. US and UC are the mean velocities of the suspension and cells, respectively. In
narrow tubes, US < UC which gives HT < Hd and it implies that HT=Hd decreases with
decrease in tube diameter. This phenomenon is called Fahraeus effect. A further decrease in
tube diameter below approximate 30 μm and less, we find an increase inHT=Hd, which known
as inverse Fahraeus effect (Figure 7). The dependence of HT=Hd on tube diameter D (in μm)
and discharge hematocrit Hd is compiled by Pries et al. [64] and is written as
HT
Hd
¼ Hd þ 1Hdð Þ 1þ 1:7e
0:415d  0:6e0:011d
 
: (53)
Consider a Newtonian fluid flow through the vessel as cylindrical tube of diameter d. Consider
the viscosity at the core region and outside the core region (or at plasma region) as μ and μ0,
respectively. Considered the continuity of velocity and stresses at the interface of the core and
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outer region while a non-slip condition on the tube of the wall. Using the abovementioned
assumption, the velocity profile of the fluid as a function of radial coordinates r is written as
u ¼
Pz
4μ
d
2
 2
 r2
" #
, λd2 ≤ r ≤ d=2,
Pz
4μ0
λd
2
 2
 r2
" #
þ
Pz
4μ
d
2
 2
1 λ2
 
, 0 ≤ r ≤ d=2,
8>>><
>>>:
(54)
where Pz represents the pressure gradient along the tube axis, λ is a constant which lies
between 0 and 1, and λd is the diameter of the core region with d as the diameter of the
cylinder (vessel).
Using Eqs. (52) and (53), the Fahraeus-Lindqvist effect and Fahraeus effects (Pries et al. [65])
are evaluated as
μapp ¼
μ
1 1
μ
μ0
 	
P4z
,
HT
Hd
¼
1
2
1 P4z 1
μ
μ0
 	
1 P2z 1
μ
2μ0
 	 : (55)
In the limit of λ approaching 0, we haveHT=Hd! 1/2 and μapp=μ! 1, and in the other way for
the limit of λ approaching 1, we have HT=Hd ! 1 and μapp=μ!μ0=μ.
Figure 6. Schematic drawings of red cells flowing through narrow glass tubes. The flow is from right to left. The left panel
is at low hematocrit, and the right panel is at high hematocrit. Single-file flow is always present in smaller tubes, whereas
transition to “zipper” or multi-file flow may occur at higher hematocrit in tubes larger than approximately 7 μm
(Gaehtgens [66]).
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4.1. Saffman lift force
Saffman lift force is mainly effective for small particles in the shear field. During drug targeting,
we always used carrier particles with nanosizes, and so the particles experience a lift force
perpendicular to the direction of the flow, which is known as Saffman lift force. The shear lift
originates from the inertia effect in the viscous flow around the particle, and it can be defined as
(Zheng and Silber-Li [67])
Fsaff ¼ 8k
0
μ
ffiffiffiffiffiffiffiffi
_γ=ν
q
R2cp vf  vcp
 
, (56)
where _γ is the shear rate of the fluid and k0 is the shape factor.
Figure 7. (a) Relative apparent viscosity of blood and (b) hematocrit ratio HT/HD, as a function of tube diameter. Solid
and dashed curves, empirical fit to in vitro experimental data for blood flow in glass tubes (Eqs. (52), (53), and (55));
Dotted curves, prediction by the stacked-coins model Eq. (55); filled circles, theoretical predictions based on axisymmetric
geometries at cell velocity = 1 mm/s (Secomb et al. [68]; Secomb [69]). Eqs. (52) and (55) at HD = 0.45 are represented by
solid curves, corresponding to normal states.
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5. Buoyant force
For the large artery of diameter more than 1000 μm, the buoyant force plays a vital role with
the convective term due to the mass of the carrier particle. The buoyant force acting on the
carrier particle during its motion in the microvessel is written as
Fb ¼ Vcp ρcp  ρf
 	
gx, (57)
where g is the gravitational acceleration and Vcp is the volume of the carrier particle.
6. Geometry of the microvessel
The geometry of the microvessel is not uniform throughout the cardiovascular system. Differ-
ent geometries of the vessel have been observed in the cardiovascular system, such as bifur-
cated vessel, with atherosclerosis inside the vessel which is attached with the wall of the vessel,
curved vessel, and so on. The flow phenomenon is very complex and interesting when blood
flows through curved or bifurcated or stenosed artery. Sometimes secondary flow appears
near the apex of the bifurcation vessel or near stenosis. In general, numerical simulations are
performed to obtain better insights into the theoretical analysis with computational fluid
dynamics (Wang et al. [57]; Pourmehran et al. [17]).
7. Inertia force
Inertia force is playing an important role in blood flow through a vessel with a large diameter.
In general we may use carrier particles with large radius, which can easily capture the tumor
position. In general multiplication of mass of the carrier particle (which is actually same as the
velocity of fluid) and acceleration of carrier particles (which is same as the acceleration of the
blood flow in vessel) is not negligible, and it gives a significant influence in the magnetic drug
targeting.
8. Equation of motion
Equation of the motion is followed by Newton’s second law of motion. According to this law,
the total force on any particle is equal to the multiplication of mass and acceleration of the
particle. According to this law, the equation of motion is written as
mcp
dvcp
dt
¼ Sumof All forces ¼ Fm þ Ff þ Fsaff þ Fb, (58)
where mcp is the mass of the carrier particle.
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Equation (58) represents the force equation in the presence of inertia force. While in the
absence of inertia force, when the diameter of the vessel is very small, then the right part of
the Eq. (58) is negligible, and the equation of motion can be written as
0 ¼ Sumof All forces ¼ Fm þ Ff þ Fsaff þ Fb: (59)
9. Conclusion and future work
Magnetic drug targeting is one of the very useful and biocompatible noninvasive methods.
Still there are many scopes left to study and build different mathematical models. There are
several factors that directly and indirectly act on the drug targeting and influence the trajectory
of the carrier particle. Moreover, here the main focus is on the magnetic drug targeting in the
cardiovascular, more particularly in the microvessel. Several experimental works have been
done in this direction, which can be implemented as mathematical models. Also, magnetic
drug targeting is effective for other human systems such as renal system, gastrointestinal tract,
and so on.
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